Key takeways from our Supply Chain Benchmark for Pharma and Life Sciences

Breakline

Scope 3 emissions are widely recognised as the hardest part of the net-zero journey, especially in pharmaceutical and healthcare supply chains. Through Impact Stewards’ Sustainable Supply Chain Initiative (SSCI), 12 healthcare organisations come together to assess where they truly stand. This supply chain benchmark for pharma and life sciences provides a sobering but constructive reality check.

7 takeaways

What does the Sustainable Supply Chain Benchmark for pharma and life sciences teach us?

1. Strategy & footprint decisions rarely integrate carbon impact

One of the clearest findings from the sustainable supply chain benchmark that participants still prioritise business impact over carbon impact. Supply chain configurations do not yet consistently factor in emissions. Concepts such as carbon-to-serve exist in theory, but are not embedded in strategic decision-making or network design.

2. Sustainability reporting is compliant – but fragmented

All participants in the benchmark comply with ESRS requirements. That’s good news. However, the supply chain function does not structurally monitor or report emissions across the value chain. This limits the ability to review sustainability targets consistently at senior leadership level.

3. Sustainable and ethical sourcing is uneven across pharma supply chains

Procurement plays a central role in reducing Scope 3 emissions. While most of the participants’ suppliers meet ethical and environmental criteria, gaps remain. Strengthening supply chain resilience and reducing long-term supply risks should be integrated more explicitly, yet such initiatives are still limited in practice.

4. Data & planning are available, but not integrated

Participants generally have relevant operational KPIs and early carbon-monitoring concepts in place. However, the supply chain benchmark reveals that sustainability trade-offs are not formally integrated into planning processes or supply chain KPIs, keeping carbon outside core steering mechanisms.

5. Social impact is recognised but not operationalised

All participants actively pursue social impact initiatives and acknowledge responsibility beyond their own walls. A very welcome attitude.  Supply chain leaders could do more, however. Why not focus on the social responsibility in the supply chain itself, from a shared definition. Nor are there measurable goals to guide actions.

6. Waste and emissions reduction stop at own operations

Participants monitor emissions and waste within their own assets, but concrete, successful reduction projects across the supply chain are scarce. Clear reduction targets for supply chain waste and emissions are largely missing.

7. Collaboration exists – impact does not (yet)

Intent to collaborate with suppliers and logistics partners is strong among participants in the supply chain benchmark. However, tangible collaborative innovations or joint emission-reduction projects have yet to materialise. Execution remains the key challenge.

The sustainable supply chain benchmark for pharma and life sciences unites organisations to assess where they truly stand. The result is a sobering but constructive reality check.

– Tim van Rees, supply chain expert

Bottom line for pharma & life sciences

Awareness is no longer the problem. The SSCI shows that the next phase requires moving from intent to integration: embedding carbon into decisions, aligning incentives with partners, and treating carbon-to-serve with the same rigor as cost-to-serve.

The real question is no longer why Scope 3 is hard – but how fast we are willing to change the way we run our supply chains.

Join the supply chain benchmark for pharma

Are you a leader in supply chain management in pharma or life sciences? Do reach out to discuss insights and opportunities to join our benchmark.

Curious what we can do for you?

Tim van Rees

tim.vanrees@impactstewards.com